invoX states its vision is to develop, manufacture and supply complex respiratory drug-device combination and medicinal products to patients. invoX has a pipeline of drug candidates in respiratory therapeutics at clinical and pre-clinical stages.
Based on the company’s public LinkedIn information, supplied through RevenueBase.
invoX has developed innovative and generic drug-device combination products using its proprietary next-generation soft mist inhaler platform, Softhaler®.
Source: LinkedIn company description · Retrieved October 13, 2026
Softhaler® uses technology to deliver propellant-free liquid-based formulation to the lung.
Source: LinkedIn company description · Retrieved October 13, 2026
Supported appearances on published RevenueBase lists, including available memberships beyond displayed rankings.
Positions describe ordering within each source list. See how lists are built ↗
Embeddable award for your website
Open the published source list.RevenueBase prepared this profile from the company’s public LinkedIn information and RevenueBase company data. These source records were retrieved on October 13, 2026. AI helped summarize these sources, with a separate automated check against the source text completed on November 4, 2026. Directory positions use company-contact counts from separate saved list snapshots dated September 14, 2026, September 15, 2026, September 16, 2026, September 18, 2026, September 19, 2026, September 20, 2026, September 21, 2026 and October 7, 2026. How the company lists are built.
Share a correction, your relationship to the company, and supporting sources. Requests are reviewed before changes are published.
Explore more companies by name, headquarters and business focus.
